Renflexis Now Reimbursed in British Columbia for Ankylosing Spondylitis, Other Indications

British Columbia is now reimbursing ankylosing spondylitis treatment Renflexis (infliximab-abda) under its public drug plan, according to Merck Canada. Besides adults with ankylosing spondylitis, the reimbursement — effective Aug. 21 — covers all other approved indications. Those include treatment of adult patients with rheumatoid arthritis, psoriatic arthritis…

Renflexis, a Remicade Biosimilar, Is Now Available in the US

Renflexis (infliximab-abda), a biosimilar of Remicade (infliximab), is now available in the United States for the treatment of ankylosing spondylitis and other conditions. The launch was recently announced by Samsung Bioepis as the company’s first biosimilar approved in the U.S. Renflexis was approved by the U.S. Food and Drug Administration (FDA) in…